Patients with Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nmsc)
Recommended Citation
Ly L, Bunick C, Stein Gold L, Vleugels R, Chovatiya R, Cotter D, Zirwas M, Luna P, Chu C, Grada A, Dilley D, Oza M, Yue E, Pechonkina A, Wegrzyn L, Levy G, Silverberg J. Patients with Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nmsc). Australas J Dermatol 2026; 67:1.
Document Type
Conference Proceeding
Publication Date
5-12-2026
Publication Title
Australas J Dermatol
Keywords
Dermatology
Abstract
Aim: To evaluate long-term incidence rates of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and malignancy (excluding nonmelanoma skin cancer, NMSC) by cardiovascular (CV) risk category in patients with moderate-to-severe atopic dermatitis (AD) treated with up to 6 years of upadacitinib (UPA), compared with background rates in a real-world US AD population. Method: Data were pooled from three phase 3, randomized, double-blind studies (Measure Up 1 and 2, AD Up) involving adolescents and adults with moderate-to-severe AD receiving UPA 15 mg or 30 mg daily. Incidence rates (per 100 patient-years; n/100 PY) of adjudicated MACE (CV death, nonfatal myocardial infarction, or nonfatal stroke), VTE (deep vein thrombosis or pulmonary embolism), and malignancy (excluding NMSC) were evaluated by baseline CV risk factors ( ≥ 1 vs 0, and stratified by 1 or 2 risk factors). These rates were compared to a reference US AD population identified by claims data, weighted by age and sex to match the UPA trial population. Results: In the UPA cohort (n = 2,683; 44-47% female; mean age ~ 32 years), CV risk factors (e.g., hypertension, diabetes, tobacco use, dyslipidemia) were present in ~ 51–54% of patients. Incidence rates of MACE, VTE, and malignancy (excluding NMSC) were low and comparable across UPA 15 mg and 30 mg groups, regardless of baseline CV risk factors (all ≤ 0.7/100 PY). These rates were similar to, or lower than, those observed in the US real-world AD population. Increasing number of baseline CV risk factors did not materially increase incidence rates during up to 6 years of UPA treatment. Conclusion: Long-term treatment with UPA in moderate-to-severe AD is associated with low rates of MACE, VTE, and malignancy (excluding NMSC), consistent across CV risk categories, supporting the favorable benefit-risk profile of UPA in this population.
Volume
67
First Page
1
